GSK on Tuesday said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio.
Reuters: GSK boosts respiratory portfolio with $1.4 billion Aiolos Bio deal
Important information - This article isn’t personal advice. If you’re not sure whether an investment is right for you please seek advice. If you choose to invest the value of your investment will rise and fall, so you could get back less than you put in.